Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) just unveiled an announcement.
Venus Medtech (Hangzhou) Inc. has announced a board meeting scheduled for August 28, 2025, to review and approve the interim results for the first half of 2025. The meeting will also consider the recommendation of an interim dividend and address other business matters, potentially impacting the company’s financial strategy and stakeholder interests.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a company incorporated in the People’s Republic of China, operating in the medical technology industry. It focuses on developing and providing innovative medical devices, particularly in the cardiovascular field.
Average Trading Volume: 4,686,120
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.98B
For an in-depth examination of 2500 stock, go to TipRanks’ Overview page.